Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Gary Bloomgren"'
Autor:
Kimberley McKinnell, Maria A. Sullivan, Priya Jain, James Fratantonio, Prashanthi Vunnava, Sarah C. Akerman, Avani Desai, Made Wenten, Gary Bloomgren, Marie A. Liles-Burden, Rose Marino
Publikováno v:
Drug Safety
Introduction After treatment with naltrexone extended-release injectable suspension (XR-NTX), a µ-opioid receptor antagonist, opioid tolerance is reduced from pretreatment baseline. Patients may be vulnerable to opioid overdose if they attempt to ov
Publikováno v:
Schizophrenia Bulletin
Background The comorbid medical and psychiatric burden for individuals with schizophrenia in the United States is substantial compared with the general population. This study sourced the IBM® MarketScan® Research Databases to examine disease preval
Publikováno v:
CNS Spectrums. 26:157-157
ObjectiveDisease prevalence, comorbid conditions, and pharmacological treatments were examined in a large population of US commercial- or Medicaid-insured individuals with schizophrenia.MethodsThis retrospective, cross-sectional claims analysis sourc
Autor:
Maria A. Sullivan, Alexandra Silveira, Gary Bloomgren, James Fratantonio, Bernard L. Silverman, Priya Jain, Sarah C. Akerman, Kimberley Marcopul
Publikováno v:
Drug Safety
Autor:
Tuan Dong-Si, Amy Gangadharan, James D. McIninch, Madé Wenten, Thomas Weber, Sarah Gheuens, Nancy Richert, Gary Bloomgren, Jeffrey Philip, Sandra Richman, Carmen Bozic, David B. Clifford, Shoibal Datta
Publikováno v:
Journal of Neurovirology
Natalizumab, a highly effective therapy for relapsing-remitting multiple sclerosis, is associated with a risk of progressive multifocal leukoencephalopathy (PML). The objective of this analysis was to examine factors predicting survival in a large na
Publikováno v:
BMC Neurology
Patients with multiple sclerosis (MS) or Crohn’s disease (CD) being treated with natalizumab (Tysabri®, Biogen) who are planning to become pregnant or discover they are pregnant after exposure to natalizumab are currently advised to balance the po
Autor:
James V. Scanlon, Meena Subramanyam, Tatiana Plavina, Alfred Sandrock, Gary Bloomgren, Sandra Richman, Amy Natarajan, Carmen Bozic
Publikováno v:
Annals of Neurology. 70:742-750
Objective: A study was undertaken to define the prevalence of anti-JC virus (JCV) antibodies in multiple sclerosis (MS) patients and to evaluate the analytical false-negative rate of a 2-step anti-JC virus antibody assay. Methods: STRATIFY-1 is an on
Autor:
Sarah Gheuens, Madé Wenten, Jeffrey Philip, Mike P. Wattjes, Tuan Dong-Si, Nancy Richert, Shoibal Datta, Gary Bloomgren, Sandra Richman, Carmen Bozic, James D. McIninch
Publikováno v:
Dong-Si, T, Richman, S, Wattjes, M P, Wenten, M, Gheuens, S, Philip, J, Datta, S, McIninch, J, Bozic, C, Bloomgren, G & Richert, N 2014, ' Outcome and survival of asymptomatic PML in natalizumab-treated MS patients ', Annals of Clinical and Translational Neurology, vol. 1, no. 10, pp. 755-764 . https://doi.org/10.1002/acn3.114
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology, 1(10), 755-764. John Wiley and Sons Ltd
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology, 1(10), 755-764. John Wiley and Sons Ltd
Objective As of 3 September 2013, 399 cases of natalizumab-associated progressive multifocal leukoencephalopathy (PML) were confirmed in multiple sclerosis (MS) patients. We evaluated outcomes of natalizumab-treated MS patients who were asymptomatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1469d66535118335ff823a97753ebc3
https://research.vumc.nl/en/publications/e7874827-aa2f-40b1-a80c-60d281c73fc1
https://research.vumc.nl/en/publications/e7874827-aa2f-40b1-a80c-60d281c73fc1
Autor:
Sophia Lee, Sandra Richman, Meena Subramanyam, Carmen Bozic, Susan Goelz, James V. Scanlon, Amy Natarajan, Tatiana Plavina, Gary Bloomgren, Christophe Hotermans, Alfred Sandrock
Publikováno v:
The New England journal of medicine. 366(20)
Progressive multifocal leukoencephalopathy (PML) is associated with natalizumab treatment. We quantified the risk of PML in patients with multiple sclerosis, according to the presence or absence of three risk factors: positive status with respect to
Publikováno v:
Annals of Neurology. 72:296-297